What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Mineralys' pill cuts blood pressure in kidney disease patients
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Capital International Investors Sells 505,624 Shares of Mineralys Therapeutics, Inc. $MLYS
Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Rating of “Moderate Buy” by Analysts
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS)
Dow Eyes Best Day in 10 Months as Tech Rebound Lifts Sentiment
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $252,469.75 in Stock
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Adam Scott Levy Sells 10,758 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Jon Congleton Sells 16,236 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
SG Americas Securities LLC Sells 23,950 Shares of Mineralys Therapeutics, Inc. $MLYS
David Malcom Rodman Sells 70,037 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of “Moderate Buy” by Brokerages
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet